Timm Crowder has joined Aerami Therapeutics as its chief operating officer, the same role he held most recently at Spyryx Biosciences. His experience also includes positions at GlaxoSmithKline (NYSE: [[ticker:GSK]]) and Oriel Therapeutics. Durham, NC-based Aerami is developing aerosol formulations of drugs that are administered via its “smart inhaler” technology. The company’s lead product candidate, inhalable insulin, is ready for late-stage testing in type 1 and type 2 diabetes.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
